If you have health care stocks in your portfolio, you should certainly look at Edward Owens is doing with health care stocks. Mr. Owens averaged 16.2% a year since the fund incepted in 1984. Over the past 10 years, the average health care funds returned 3.86% a year, while Mr. Owens’ fund gained 6.27% a year.

This is the portfolio chart of Edward Owens. You can click on the legend of the chart to show/hide buys, sells, or holdings. Each ball on the chart represents a position in the portfolio. You can move your mouse on the balls to see the details of each position and click to see the details of all guru trades with this position.

Edward Owens added to his holdings in Medtronic Inc by 52.77%. His purchase prices were between $30.41 and $38.2, with an estimated average price of $34.75. The impact to his portfolio due to this purchase was 0.69%. His holdings were 11,001,100 shares as of 09/30/2011.

Medtronic is the world's medical technology company, pioneeringdevice-based therapies that restore health, extend life and alleviate pain. Medtronic Inc has a market cap of $36.68 billion; its shares were traded at around $34.74 with a P/E ratio of 10.3 and P/S ratio of 2.3. The dividend yield of Medtronic Inc stocks is 2.8%. Medtronic Inc had an annual average earnings growth of 10.1% over the past 10 years. GuruFocus rated Medtronic Inc the business predictability rank of 4-star.

Edward Owens added to his holdings in Teva Pharmaceutical Industries Ltd. by 231.25%. His purchase prices were between $35.26 and $49.47, with an estimated average price of $41.94. The impact to his portfolio due to this purchase was 0.38%. His holdings were 2,650,000 shares as of 09/30/2011.

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva Pharmaceutical Industries Ltd. has a market cap of $36.36 billion; its shares were traded at around $40.85 with a P/E ratio of 8.7 and P/S ratio of 2.3. The dividend yield of Teva Pharmaceutical Industries Ltd. stocks is 1.9%. Teva Pharmaceutical Industries Ltd. had an annual average earnings growth of 20.7% over the past 10 years. GuruFocus rated Teva Pharmaceutical Industries Ltd. the business predictability rank of 4-star.

Edward Owens added to his holdings in Merck & Co. Inc. by 4.61%. His purchase prices were between $29.81 and $36.31, with an estimated average price of $33.23. The impact to his portfolio due to this purchase was 0.28%. His holdings were 35,390,648 shares as of 09/30/2011.

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck & Co. Inc. has a market cap of $106.29 billion; its shares were traded at around $34.5 with a P/E ratio of 9.3 and P/S ratio of 2.3. The dividend yield of Merck & Co. Inc. stocks is 4.4%.

Edward Owens added to his holdings in Bristol Myers Squibb Co by 8.84%. His purchase prices were between $26.38 and $31.49, with an estimated average price of $29.18. The impact to his portfolio due to this purchase was 0.17%. His holdings were 12,003,061 shares as of 09/30/2011.

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions. Bristol Myers Squibb Co has a market cap of $53.88 billion; its shares were traded at around $31.59 with a P/E ratio of 14.2 and P/S ratio of 2.8. The dividend yield of Bristol Myers Squibb Co stocks is 4.2%. Bristol Myers Squibb Co had an annual average earnings growth of 15% over the past 5 years.

Edward Owens added to his holdings in United Therapeutics Corp. by 77.9%. His purchase prices were between $37.47 and $57.38, with an estimated average price of $48.47. The impact to his portfolio due to this purchase was 0.16%. His holdings were 1,787,000 shares as of 09/30/2011.

UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. United Therapeutics Corp. has a market cap of $2.55 billion; its shares were traded at around $43.73 with a P/E ratio of 14.5 and P/S ratio of 4.2.

Edward Owens added to his holdings in Zimmer Holdings Inc by 25%. His purchase prices were between $50.98 and $65.73, with an estimated average price of $57.69. The impact to his portfolio due to this purchase was 0.12%. His holdings were 2,000,000 shares as of 09/30/2011.

Zimmer is a global leader in the design, development, manufacturing and market of reconstructive orthopaedic implants and fracture management products. Zimmer Holdings Inc has a market cap of $10.02 billion; its shares were traded at around $52.63 with a P/E ratio of 11.2 and P/S ratio of 2.4. Zimmer Holdings Inc had an annual average earnings growth of 14.9% over the past 10 years.

Edward Owens added to his holdings in Tenet Healthcare Corp by 940%. His purchase prices were between $4.03 and $6.48, with an estimated average price of $5.24. The impact to his portfolio due to this purchase was 0.11%. His holdings were 5,200,000 shares as of 09/30/2011.

Tenet Healthcare Corp. is an investor-owned health care services company. Tenet Healthcare Corp has a market cap of $2.19 billion; its shares were traded at around $4.73 with a P/E ratio of 13.9 and P/S ratio of 0.2. Tenet Healthcare Corp had an annual average earnings growth of 10.9% over the past 5 years.

Edward Owens added to his holdings in Salix Pharmaceuticals Ltd. by 55.43%. His purchase prices were between $26.18 and $40.9, with an estimated average price of $33.07. The impact to his portfolio due to this purchase was 0.09%. His holdings were 1,554,300 shares as of 09/30/2011.

Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. Salix Pharmaceuticals Ltd. has a market cap of $2.02 billion; its shares were traded at around $34.255 with a P/E ratio of 25.2 and P/S ratio of 6.

Edward Owens added to his holdings in Cubist Pharmaceuticals Inc. by 49.25%. His purchase prices were between $29.59 and $36.93, with an estimated average price of $34.13. The impact to his portfolio due to this purchase was 0.08%. His holdings were 1,323,142 shares as of 09/30/2011.

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubist Pharmaceuticals Inc. has a market cap of $2.31 billion; its shares were traded at around $37.81 with a P/E ratio of 23.5 and P/S ratio of 3.6.

Edward Owens added to his holdings in Vanguard Health Systems Inc by 31.47%. His purchase prices were between $10.39 and $18, with an estimated average price of $14.31. The impact to his portfolio due to this purchase was 0.03%. His holdings were 2,556,780 shares as of 09/30/2011.

Vanguard Health Systems Inc. is engaged in the ownership and operation of acute care hospitals, outpatient facilities, and related health plans. Vanguard Health Systems Inc has a market cap of $694.8 million; its shares were traded at around $9.72 with and P/S ratio of 0.1.

Edward Owens initiated holdings in Hca Holdings Inc.. His purchase prices were between $17.66 and $34.61, with an estimated average price of $23.95. The impact to his portfolio due to this purchase was 0.32%. His holdings were 2,900,000 shares as of 09/30/2011.

HCA Inc. is a non-governmental hospital in the U.S. Hca Holdings Inc. has a market cap of $12.13 billion; its shares were traded at around $23.45 with a P/E ratio of 3.5 and P/S ratio of 0.4.

Edward Owens initiated holdings in Aflac Inc. His purchase prices were between $31.46 and $47.4, with an estimated average price of $39.45. The impact to his portfolio due to this purchase was 0.1%. His holdings were 500,000 shares as of 09/30/2011.

AFLAC Inc. is a general business holding company and acts as a management company, overseeing the operations of its subsidiaries by providing management services and making capital available. Aflac Inc has a market cap of $21.06 billion; its shares were traded at around $45.09 with a P/E ratio of 7.3 and P/S ratio of 1. The dividend yield of Aflac Inc stocks is 2.7%. Aflac Inc had an annual average earnings growth of 10.9% over the past 10 years. GuruFocus rated Aflac Inc the business predictability rank of 3.5-star.

New Purchase: CVS Caremark Corp (CVS)

Edward Owens initiated holdings in CVS Caremark Corp. His purchase prices were between $32.06 and $38.54, with an estimated average price of $35.73. The impact to his portfolio due to this purchase was 0.04%. His holdings were 200,000 shares as of 09/30/2011.

CVS/Caremark is the nation's premier integrated pharmacy services provider, combining one of the nation's pharmaceutical services companies with the country's largest pharmacy chain. Cvs Caremark Corp has a market cap of $48.86 billion; its shares were traded at around $36.3325 with a P/E ratio of 13.6 and P/S ratio of 0.5. The dividend yield of Cvs Caremark Corp stocks is 1.4%. Cvs Caremark Corp had an annual average earnings growth of 13.4% over the past 10 years. GuruFocus rated Cvs Caremark Corp the business predictability rank of 4.5-star.

New Purchase: Healthsouth Corp (HLS)

Edward Owens initiated holdings in Healthsouth Corp. His purchase prices were between $14.81 and $26.88, with an estimated average price of $21.06. The impact to his portfolio due to this purchase was 0.03%. His holdings were 386,000 shares as of 09/30/2011.

HEALTHSOUTH Corp. is the one of the nation's largest providers of outpatient surgery and rehabilitative healthcare services. Healthsouth Corp has a market cap of $1.68 billion; its shares were traded at around $17.66 with a P/E ratio of 15.1 and P/S ratio of 0.8.

Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.
Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.